Compounding Pharmacy Networks (503A/503B)
How Telehealth Uses Compounding to Sell Non-FDA-Approved Formulations
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Compounded drugs are not FDA-approved; lawful only under 503A/503B exemptions
Reference only. Not medical advice.
What can go wrong
Compounded drugs lack FDA pre-market review for safety, efficacy, and manufacturing consistency. Documented risks include sub- or super-potency, contamination, and, in the GLP-1 wave, dosing errors. Regulators have escalated enforcement, including a reported wave of roughly 100 cease-and-desist letters to compounders and telehealth providers in September 2025.
This is something to take to a clinician. The Atlas can tell you what is known about compounding pharmacy networks (503a/503b) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Compounding pharmacies prepare customized medications outside the FDA new-drug-approval process under two carve-outs of the Federal Food, Drug, and Cosmetic Act: section 503A (patient-specific compounding by traditional pharmacies) and section 503B (registered outsourcing facilities operating under cGMP that may batch-produce without patient-specific prescriptions). Telehealth platforms route prescriptions to these pharmacies to sell formulations that are not individually FDA-approved, compounded tadalafil 'troches,' combination ED tablets, testosterone creams, and (while shortages lasted) compounded GLP-1s.
The legal channel for selling drugs the FDA never approved.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Compounded products skip the FDA approval that proves safety and efficacy. They are lawful when made for an individual patient (503A) or by a registered outsourcing facility (503B), and copies of approved drugs are generally only permissible during a documented shortage. Telehealth platforms exploit this by offering 'personalized' formulations, e.g., a tadalafil troche with added ingredients, that let them differentiate, set their own prices, and sidestep both the branded drug's patent/price and, in some cases, the absence of any approved version of the formulation.
The Catch: 'Personalized' Often Means 'Unapproved and Untested'
Marketing often presents compounded products as equivalent or superior to approved drugs ('same active ingredient, better delivery'). But compounded formulations are not tested for bioequivalence, and 'personalization' is frequently a templated upsell rather than a clinical judgment. Sterility and potency failures at compounding facilities have caused real harm historically (the 2012 NECC meningitis outbreak prompted the 2013 Drug Quality and Security Act that created the 503B category).
Safety in detail
Compounded hormone and sexual-health products are not FDA-approved and are not tested for bioequivalence, safety, or manufacturing consistency. Use without qualified physician evaluation and monitoring carries documented health risks, including from potency variability and contamination.
Replacement is not the same as a cycle
Compounded testosterone creams and troches can deliver a wide and inconsistent dose range. Without FDA-verified potency and without rigorous monitoring, men can drift from physiological replacement into supraphysiological (anabolic) exposure, carrying erythrocytosis, cardiovascular, and fertility-suppression risks. Compounding does not make supraphysiological dosing safe; it removes a layer of manufacturing oversight.
What people get wrong
Often saidA compounded tadalafil troche is the same as approved Cialis, just better-absorbed
ActuallyCompounded troches are not tested for bioequivalence and are not FDA-approved; the 'better delivery' claim is typically a marketing differentiator, not a demonstrated clinical advantage.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Compounding pharmacies (503A and 503B outsourcing facilities), the telehealth platforms and clinics that route prescriptions to them, and the prescribers paid per consult.
What we do not know
- How will states (e.g., telehealth-prescribing parity) and the FDA reconcile 'personalization' claims with the lack of bioequivalence testing?
- Will GLP-1 enforcement spill into compounded testosterone and tadalafil scrutiny?
At a glance
- 503A
- Patient-specific compounding; state-board regulated
- 503B
- Registered outsourcing facility; cGMP; may batch
- FDA status of compounded drugs
- Not FDA-approved for safety/efficacy
- 2025 enforcement
- ~100 cease-and-desist letters reported to compounders/telehealth in Sept 2025
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Compounding Pharmacy Networks (503A/503B). A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.